首頁 > 市場調查報告書 > 製藥

癌症分子標靶治療學

市場調查報告書

商品編碼

1833290

CD40標靶治療藥的全球市場:臨床試驗，治療方法，專利技術平台，市場機會相關洞察(2026年)

Global CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

出版日期: 2025年10月01日 | 出版商:

KuicK Research | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球 CD40 標靶治療市場 - 臨床試驗、治療方法、專有技術平台及市場機會洞察（2026 年）報告結果與亮點

首個 CD40 標靶治療預計將於 2027 年獲批
臨床試驗中的 CD40 標靶治療：超過 35 種療法
按公司、國家、適應症和治療階段劃分的 CD40 標靶治療臨床試驗洞察
按公司劃分的 CD40 標靶治療專有技術
按地區劃分的 CD40 標靶治療市場趨勢分析
競爭格局

對 CD40 標靶治療的需求以及本報告的意義

CD40標靶療法是免疫療法領域的一項重大突破，為自體免疫疾病、癌症甚至某些感染性疾病的治療提供了新的潛力。與通常廣泛抑制免疫系統的傳統療法不同，CD40標靶療法選擇性地靶向免疫細胞上的CD40受體，從而特異性地調節免疫反應。這種方法可以調節免疫系統，而不會產生傳統療法的普遍免疫抑制和副作用，從而有望帶來更好、更安全的治療方案。由於臨床試驗結果持續向好，CD40標靶療法正被用於治療狼瘡性腎炎、多發性硬化症和癌症等自體免疫疾病，這有可能為這些複雜疾病的治療帶來革命性的變革。

本報告對新興的CD40標靶療法市場進行了深入分析，旨在讓利害關係人了解最新進展和未來趨勢。報告對目前的臨床試驗、領先的製藥公司以及最有前景的候選藥物研發管線提供了獨特的見解。此外，本報告也探討了可能推動開發更具針對性和有效性的CD40標靶療法的技術創新和合作措施。本報告簡要概述了市場的現狀和未來潛力，為投資者、研發專業人員和醫療保健專業人員提供了解這一快速發展市場的關鍵資訊。

報告中涵蓋的臨床試驗見解

鑑於臨床試驗對於CD40標靶療法的開發至關重要，本報告深入探討了正在進行和即將進行的臨床試驗，這些試驗將決定這些療法的未來發展。 1期臨床試驗已顯示出良好的結果，一些針對自體免疫疾病的療法已進入3期試驗。這些臨床試驗不僅開發了CD40標靶藥物的治療潛力，還確定了哪些候選藥物最有可能在更大的市場中取得成功。

本報告也簡要介紹了全球市場對這些療法日益增長的需求。雖然美國在CD40標靶研究方面處於領先地位，但中國、澳洲和歐洲部分地區等其他地區的臨床試驗規模也不斷擴大。這種地理分佈的不斷擴大反映出，CD40標靶療法目前正在全球範圍內得到探索，並在各個醫療保健市場中帶來了新的機會。

參與CD40標靶療法研發的頂尖公司

除了尖端生技公司外，許多頂尖製藥公司也在引領CD40標靶療法的研發。這些公司正在突破常規思維，創新療法，這些療法可能會徹底改變自體免疫疾病、癌症和其他疾病的治療。一些候選藥物已進入後期臨床試驗階段，而另一些則處於早期開發階段，並已顯示出良好的臨床前數據。

本報告概述了在CD40標靶療法研究方面處於領先地位的行業領袖的努力。這些公司正在利用先進技術和科學創新來提高治療的安全性和有效性。製藥、生物技術和學術界之間的聯盟與合作也正在加速開發進程，並建立合作關係，這將在不久的將來帶來突破。

技術平台、合作夥伴關係和協定

本報告的很大一部分內容致力於介紹能夠設計更有效、更有針對性的CD40療法的技術進步。各公司正在應用新的平台來提高CD40標靶的特異性，最大限度地提高治療效果，同時減少副作用。一個例子是結合靶向樹突狀細胞的單株抗體和抗原，有可能更精準、更持久地增強免疫反應。

製藥、生物技術和學術界之間的合作也正在加快該領域的創新步伐。合作研究對於克服與CD40標靶療法開發相關的複雜問題（例如優化遞送機制和長期安全性問題）至關重要。本報告介紹了幾個合作研究項目，並重點介紹了該領域的一些有希望的進展。

First CD40 Targeted Therapy Approval Expected By 2027
CD40 Targeted Therapies In Clinical Trials: > 35 Therapies
CD40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase
CD40 Targeted Therapies Proprietary Technologies By Company
CD40 Targeted Therapy Market Trend Analysis By Region
Competitive Landscape

Need For CD40 Targeted Therapies & Why This Report?

CD40 targeting therapies are now emerging as a major breakthrough in immunotherapy, holding new promise for autoimmune disease, cancer, and even for certain infectious diseases. In contrast to conventional treatments, which generally dampen the immune system in a broad way, CD40 targeting therapies seek to modulate immune reactions specifically by selectively targeting the CD40 receptor on immune cells. This method may result in better and safer therapies because it can modulate the immune system without leading to the generalized immune suppression and side effects of traditional treatments. With continued encouraging findings from clinical trials, CD40 targeted therapy is being investigated for autoimmune diseases such as lupus nephritis, multiple sclerosis, and cancer, marking a groundbreaking change in the treatment of these intricate illnesses.

The report presents a detailed analysis of the emerging CD40 targeted therapy market, aimed at keeping stakeholders up to date with the recent advancements and upcoming trends. The report provides unique insights into current clinical trials, major pharmaceutical companies, and the most promising pipeline drug candidates. Additionally, the report explores technological innovations and collaborative initiatives that are driving the development of more targeted and efficacious CD40 targeting therapies. With both a snapshot of the present state of the market as well as its future potential, the report arms investors, researchers, and healthcare professionals alike with critical information to make sense of this fast developing space.

Clinical Trials Insight Covered In Report

With clinical trials remaining central to the development of CD40 targeted therapies, this report looks closely at the ongoing and upcoming trials that are defining the future of the therapies. Phase trials have already demonstrated encouraging results, with certain therapies progressing to Phase 3 trials for autoimmune conditions. Such trials serve not only to develop the therapeutic potential of CD40 targeting agents but also to determine which drug candidates have the greatest likelihood of success in the larger market.

The report also briefly addresses the increasing demand for such therapies in global markets. As great a lead as the US has taken with CD40 targeted research, there has been a growing presence of trials in other areas, including China, Australia, and parts of Europe. The fact that this geographical presence is broadening reflects the fact that CD40 targeted therapies are now being considered all over the world, with new opportunities in different healthcare markets.

Top Companies Involved In R&D Of CD40 Targeting Therapy

A number of top pharmaceutical companies, in addition to cutting edge biotech companies, are leading research and development in CD40 targeted therapy. These corporations are breaking the mold, innovating new therapies that have the potential to profoundly transform the treatment of autoimmune diseases, cancers, and more. Some candidates are in later clinical stages, while others are still in early development but are indicating encouraging preclinical data.

This report highlights the efforts of leading players in the industry that are pioneering the research in CD40 targeting therapies. These players are making use of advanced technologies and scientific innovations to enhance the safety and efficacy of the therapies. Alliances and collaboration between pharmaceutical firms, biotech companies, and academia are also speeding up the process of development, establishing a collaborative system that will culminate in breakthroughs in the near term.

Technology Platforms, Partnerships & Agreements

Much of the report is dedicated to the technological advancements that are making it possible to design more potent and targeted CD40 treatments. Novel platforms are being applied by companies to increase the specificity of CD40 targeting, reducing side effects while maximizing therapeutic effect. The case in point is incorporating monoclonal antibodies and antigens to target dendritic cells, which might increase the immune response in a more precise and long lasting fashion.

Pharma, biotech, and academic collaborations are also speeding up the innovation rate in the field. The collaborations are needed to overcome the complexity issues related to the development of CD40 targeted therapy, including optimization of the delivery mechanisms as well as long term safety issues. The report highlights some of the collaborations and alludes to the promising advances being made in the field.

1. Introduction To CD40 Targeted Therapies

1.1 Overview
1.2 Considering CD40 As Drug Target Over Other CD Markers
1.3 History & Evolution Of CD40 Targeting Therapies

2. CD40 Targeted Therapies - Mechanism Of Action

2.1 Agonist Mediated Activation Of CD40 Signaling
2.2 Antagonist Mediated Inhibition Of CD40 Signaling

3. CD40 Targeted Therapeutic Approaches

3.1 Antibody Formats
3.2 Fusion Proteins
3.3 Peptides
3.4 Nucleic Acids

4. CD40 Targeted Therapy Research & Development Trends By Indication

4.1 Cancer
4.2 Neurological Diseases
4.3 Autoimmune & Inflammatory Disorders
4.4 Transplant Rejection
4.5 Microbial Infections

5. CD40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase I/II
5.5 Phase II
5.6 Phase III

6. Global CD40 Targeted Therapy Market Outlook

6.1 Current Market Trends & Developments
6.2 Future Market Opportunities

7. CD40 Targeted Therapy Market Trend Analysis By Region

7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 Australia

8. CD40 Targeted Therapies - Proprietary Technologies By Company

9. Global CD40 Targeted Therapy Market Dynamics

9.1 Drivers & Opportunities
9.2 Challenges & Restraints

10. Competitive Landscape

10.1 Alligator Bioscience
10.2 Amgen
10.3 Biogen
10.4 BioNTech
10.5 Eledon Pharmaceuticals
10.6 EnnoDC
10.7 Genmab
10.8 Innovent Bio
10.9 Novartis
10.10 Sanofi
10.11 Tonix Pharmaceuticals
10.12 UCB

簡介目錄圖表

List of Figures

Figure 1-1: CD40 - Salient Features
Figure 1-2: CD40 Targeted Therapy Landscape - Major Milestones
Figure 2-1: CD40 Agonists - Mechanism Of Action
Figure 2-2: CD40 Antagonists - Mechanism Of Action
Figure 3-1: Prominent Antibody Formats For Targeting CD40
Figure 3-2: CD40 Fusion Protein Types & Properties
Figure 3-3: CD40 Fusion Proteins - Advantages & Challenges
Figure 3-4: Advantages vs. Challenges Of Peptides For CD40 Targeting
Figure 3-5: siRNA Delivery Mechanism & Effect On Immune Cells
Figure 4-1: OPTIMIZE-1 Phase 1b/2 (NCT04888312) Study - Initiation & Completion Year
Figure 4-2: Mitazalimab Phase 1 (NCT06205849) Study - Initiation & Completion Year
Figure 4-3: 2141-V11 Phase 1 (NCT06455605) Study - Initiation & Completion Year
Figure 4-4: 2141-V11 Phase 1/2 (NCT05734560) Study - Initiation & Completion Year
Figure 4-5: 2141-V11 Phase 1/2 (NCT05126472) Study - Initiation & Completion Year
Figure 4-6: ACT16877 Phase 2 (NCT04879628) Study - Initiation & Completion Year
Figure 4-7: FREVIVA Phase 3 (NCT06141486) Study - Initiation & Completion Year
Figure 4-8: FREXALT 3 (NCT06141473) Study - Initiation & Completion Year
Figure 4-9: PHOENYCS FLY Phase 3 (NCT06617325) Study - Initiation & Completion Year
Figure 4-10: SL0046 Phase 3 (NCT04976322) Study - Initiation & Completion Year
Figure 4-11: HZNP-DAZ-301 Phase 3 (NCT06104124) Study - Initiation & Completion Year
Figure 4-12: HZNP-DAZ-303 Phase 3 (NCT06245408) Study - Initiation & Completion Year
Figure 4-13: VIBRANT Phase 2 (NCT05201469) Study - Initiation & Completion Year
Figure 4-14: FABULINUS Phase 2 (NCT06111586) Study - Initiation & Completion Year
Figure 4-15: APB-A1 Phase 1b (NCT06557850) Study - Initiation & Completion Year
Figure 4-16: IRB23-1367 Phase 1/2 (NCT06111586) Study - Initiation & Completion Year
Figure 4-17: AT-1501-K102 Phase 1 (NCT05027906) Study - Initiation & Completion Year
Figure 4-18: BESTOW/AT-1501-K207 Phase 2 (NCT05983770) Study - Initiation & Completion Year
Figure 4-19: BESTOW-EXTENSION/AT-1501-K209 Phase 2 (NCT06126380) Study - Initiation & Completion Year
Figure 4-20: ANRS VRI06 Phase 1 (NCT04842682) Study - Initiation & Completion Year
Figure 4-21: HVTN 318 Phase 1 (NCT06665646) Study - Initiation & Completion Year
Figure 4-22: ANRS0407s - LKV.Cov40 Phase 1/2 (NCT06255626) Study - Initiation & Completion Year
Figure 4-23: HPVDCVax Phase 1/2 (NCT06007092) Study - Initiation & Completion Year
Figure 5-1: Global - CD40 Targeted Therapies In Clinical Trials, 2025 -2026
Figure 6-1: CD40 Targeted Therapy - Future Opportunities
Figure 8-1: Alligator Bioscience - FIND technology
Figure 8-2: Alligator Bioscience - Neo-X-Prime
Figure 8-3: Aprilbio - SAFA Antibody APB-A1
Figure 8-4: Genmab - DuoBody
Figure 8-5: Harbour BioMed - Harbour Mice
Figure 8-6: Harbour BioMed - HCAb
Figure 8-7: H2L2 & HCAb Platforms - Features
Figure 8-8: Harbour BioMed - HBICE
Figure 8-9: Kyowa Kirin - REGULGENT
Figure 8-10: ADAC Technology Platform - Features
Figure 8-11: Strike Pharma - ADAC Technology Platform
Figure 8-12: Strike Pharma - ADAC Molecule
Figure 9-1: CD40 Targeted Therapy Market - Drivers & Opportunities
Figure 9-2: CD40 Targeted Therapy Market - Challenges & Restraints